Tevogen Bio Holdings Inc. (TVGN) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell technology) for infectious diseases and cancers. The primary product candidate, TVGN 489, has completed a Phase 1 proof-of-concept trial for high-risk COVID-19 patients. The company also pursues an AI initiative (Tevogen.AI) to accelerate drug development. This report covers the quarterly period ended March 31, 2026.
Effective March 6, 2026, the company executed a 1-for-50 reverse stock split.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,446,255) | $(10,367,061) |
| Net Loss Per Share (Basic & Diluted) | $(1.61) | $(3.25) |
| Operating Expenses | $5,400,920 | $10,356,347 |
| Cash and Cash Equivalents (End of Period) | $692,305 | $1,974,932 |
| Net Cash Used in Operating Activities | $(2,733,769) | $(3,308,063) |
| Total Debt (Notes Payable + Loan Agreement) | $8,051,000 | $6,051,000 |
| Stockholders' Deficit | $(9,842,158) | $(8,234,726) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $4.9 million (47%) compared to Q1 2025, primarily driven by a significant reduction in General and Administrative (G&A) expenses.
- Expense Reduction: G&A expenses dropped from $7.2 million to $2.3 million, largely due to lower non-cash stock-based compensation ($5.5M in Q1 2025 vs. $0.96M in Q1 2026) and reduced legal/professional fees.
- Debt Increase: The company drew an additional $2.0 million on its Loan Agreement with The Patel Family, LLP, increasing the outstanding balance to $6.4 million. Total debt obligations rose to $8.05 million.
- Cash Position: Cash on hand increased slightly by $140,000 to $692,305, supported by financing activities ($2.9M inflow) which offset operating cash burn.
Outlook, Risks, and Unusual Items
- Liquidity and Funding: Management believes current cash ($0.7M), combined with subsequent financing (including a $3.0M PIPE transaction in May 2026), available credit under the Loan Agreement ($14M remaining), and committed grants ($7M from KRHP), will fund operations for at least 12 months. The company does not plan to initiate new clinical trials until additional funding is secured.
- Nasdaq Compliance Risk: The company received notice from Nasdaq in April 2026 that it failed to meet the $50 million minimum market value for listed securities and the $15 million minimum market value of publicly held shares requirements. The company has 180 days (until October 2026) to regain compliance or face potential delisting.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting.
- Debt Default: Notes payable of $1.65 million assumed from the Merger are in default as they were due within five business days of the merger closing. However, default provisions do not currently require immediate repayment or share transfer.
- Subsequent Events: In May 2026, the company sold prefunded common stock purchase warrants for $3.0 million and sold approximately 278,000 shares under its Sales Agreement for net proceeds of $5.9 million.
Investor Verification Checklist
- Nasdaq Compliance Plan: Verify the specific steps management is taking to regain compliance with Nasdaq listing requirements (MVLS and MVPHS) before the October 2026 deadline.
- Debt Covenants and Default Status: Confirm the status of the $1.65 million defaulted notes payable and whether the lender (Polar) has waived the default or initiated collection.
- Internal Control Remediation: Review the company's plan to remediate the material weakness in internal controls over financial reporting.
- Grant Funding Reliability: Assess the certainty of the remaining $7.0 million grant commitment from KRHP (affiliated with the Patel Family) and any conditions attached.
- Stock-Based Compensation Volatility: Monitor future quarters for potential spikes in stock-based compensation expense, which significantly impacted the Q1 2025 results and could distort future GAAP losses.